Symbolbild · KI-generiert
Zentalis Pharmaceuticals, Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Zentalis Pharmaceuticals is a clinical-stage oncology company developing small-molecule therapies for cancer. Its lead candidate Azenosertib is a WEE1 inhibitor being investigated in clinical trials across various solid tumours.
Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. | ZNTL | NASDAQ | 337 Mio. USD |
| Agenus Inc. | AGEN | NASDAQ | 336 Mio. USD |
| Rocket Pharmaceuticals, Inc. | RCKT | NASDAQ | 340 Mio. USD |
| Standard BioTools Inc. | LAB | NASDAQ | 340 Mio. USD |
| Fennec Pharmaceuticals Inc. | FENC | NASDAQ | 334 Mio. USD |
| DiaMedica Therapeutics Inc. | DMAC | NASDAQ | 342 Mio. USD |
| Carlsmed, Inc. | CARL | NASDAQ | 342 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.